Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03046056 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Efficacy and Safety of Filgotinib in the Treatment of Small Bowel Crohn's Disease (SBCD)
A Phase 2 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 78
- Enrollment target
NCT03046056 is a Phase 2 study that has completed, run by Gilead Sciences. The registered enrollment target is 78 participants.
The verdict
NCT03046056, a Phase 2 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 78 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the efficacy of filgotinib, when compared to placebo, in establishing clinical remission defined as Crohn's disease activity index (CDAI) \< 150, at Week 24 in participants with small bowel Crohn's disease (CD). Participants will have the option to enter a separate long-term extension study if they meet eligibility requirements.
Interventions
- DRUG Filgotinib
- DRUG Placebo to match filgotinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2017-04-11 |
| Est. Completion | 2020-07-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03046056
The ClinicalTrials.gov registry entry for NCT03046056 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Filgotinib is the first listed.
NCT03046056 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03046056 about?
NCT03046056 is a clinical study titled "Study to Evaluate the Efficacy and Safety of Filgotinib in the Treatment of Small Bowel Crohn's Disease (SBCD)". The primary objective of this study is to evaluate the efficacy of filgotinib, when compared to placebo, in establishing clinical remission defined as Crohn's disease activity index (CDAI) \< 150, at Week 24 in participants with small bowel Crohn's disease (CD). Participants will have the option to ...
What is the current status of trial NCT03046056?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 78 participants. The study started on 2017-04-11. Estimated completion is 2020-07-20.
What interventions are being tested in trial NCT03046056?
The interventions under investigation include: Filgotinib (DRUG), Placebo to match filgotinib (DRUG).
Who is sponsoring clinical trial NCT03046056?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.